RET inhibitor nearly doubled PFS in RET fusion-positive advanced/metastatic NSCLC
Results from the LIBRETTO-431 trial reinforce the use of selpercatinib as the first-line choice and are likely to widen patient access to treatment
Adding amivantamab to chemotherapy prolongs PFS in untreated EGFR exon 20 insertion-mutated advanced NSCLC
The bispecific EGFR/MET-directed monoclonal antibody looks set to become the standard of care in this setting, but toxicity has to be managed carefully
New data support perioperative nivolumab for patients with resectable NSCLC
CheckMate 77T demonstrates significantly improved event-free survival with neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab compared with chemotherapy and adjuvant placebo
How can we overcome resistance to immune checkpoint inhibitors in NSCLC?
Results from studies presented at the ESMO Congress 2023 (Madrid, 20–24 October) outline different strategies involving indirect immune modulation and direct enhanced tumour cytotoxicity to improve on chemotherapy as the current standard of second-line care after ICI progression
Longer PFS reported with a quadruple treatment regimen in EGFR- or ALK-mutated NSCLC
Promising data from the ATTLAS phase III study indicate a potential new approach for treating patients progressing on TKIs
Sitravatinib plus nivolumab does not improve survival in NSCLC after immunotherapy and chemotherapy
The SAPPHIRE trial failed to meet its primary endpoint compared with chemotherapy
Clonal haematopoiesis in the tumour microenvironment is an indicator of poor prognosis in NSCLC
Results from the TRACERx study suggest a potential role of CHIP as a prognostic biomarker, but further research is needed
Cemiplimab survival improvements in NSCLC are durable
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases
New insights into targeting KRAS G12C mutations in NSCLC
Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment
Second-line atezolizumab plus cabozantinib fails to improve overall survival in metastatic NSCLC
Final OS analysis of the phase III CONTACT-01 trial reports negative results for immunotherapy versus docetaxel in patients progressing on checkpoint inhibitors plus chemotherapy